Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (141-150 of 280) with videos related to

Pageof 28
Sort By:
Cancer Chemotherapy and Pharmacology|December 12, 2012
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumorsMichael S Gordon, Robert Ilaria, Dinesh P de Alwis, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Investigational New Drugs|June 11, 2003
A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" designS M Gadgeel, R R Boinpally, L K Heilbrun, et al.
Investigational New Drugs|April 19, 2017
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumorsJanice M Mehnert, Gerald Edelman, Mark Stein, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 19, 2019
Transcranial direct current stimulation for Phantom Limb Pain circuitopathy: Efficacy and safety in a patient with a cardiac defibrillatorA Miuli, M C Spano, M Lorusso, et al.
Investigational New Drugs|July 6, 2017
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialIan E Krop, Sung-Bae Kim, Antonio Gonzalez Martin, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potentialPatricia M LoRusso, Sarina A Piha-Paul, Monica Mita, et al.
Pageof 28

Showing results (141-150 of 280) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|December 12, 2012
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumorsMichael S Gordon, Robert Ilaria, Dinesh P de Alwis, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Investigational New Drugs|June 11, 2003
A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" designS M Gadgeel, R R Boinpally, L K Heilbrun, et al.
Investigational New Drugs|April 19, 2017
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumorsJanice M Mehnert, Gerald Edelman, Mark Stein, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 19, 2019
Transcranial direct current stimulation for Phantom Limb Pain circuitopathy: Efficacy and safety in a patient with a cardiac defibrillatorA Miuli, M C Spano, M Lorusso, et al.
Investigational New Drugs|July 6, 2017
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialIan E Krop, Sung-Bae Kim, Antonio Gonzalez Martin, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potentialPatricia M LoRusso, Sarina A Piha-Paul, Monica Mita, et al.
Pageof 28